Höffler D
Dtsch Med Wochenschr. 1978 Dec 29;103(52):2071-5. doi: 10.1055/s-0028-1129399.
In a randomised double-blind study 25 patients each were treated with amikacin (375 mg/d three times i.m.) or gentamicin (three times 80 mg/d i.m.). The dose was decreased according to a predetermined schedule if there was impaired renal function. Treatment indication was urinary tract infections of different severity with gram-negative organisms resistant to penicillin and cephalosporin. The bacteriological findings of a urine sample obtained by bladder puncture three and ten days after the end of treatment were the criterion of success. In addition, the number of white cells in the urine was taken into account. On the basis of various criteria, amikacin was found to give the higher success rate. The most important criterion, disappearance of the initially demonstrated microorganism, demonstrated a statistically significant advantage of amikacin over gentamicin.
在一项随机双盲研究中,25例患者分别接受阿米卡星(375毫克/天,肌内注射,每日3次)或庆大霉素(80毫克/天,肌内注射,每日3次)治疗。如果肾功能受损,则根据预定方案减少剂量。治疗指征为不同严重程度的对青霉素和头孢菌素耐药的革兰氏阴性菌引起的尿路感染。治疗结束后第3天和第10天通过膀胱穿刺获得的尿样的细菌学检查结果为成功的标准。此外,还考虑了尿中白细胞的数量。基于各种标准,发现阿米卡星的成功率更高。最重要的标准,即最初发现的微生物消失,显示阿米卡星相对于庆大霉素具有统计学上的显著优势。